Media & Resources

Novel HIV immunogens to be delivered via novel mRNA platform.

Reflections from colleagues Pat Fast, Mark Feinberg, Margaret McCluskey, and Bill Snow.

Read on for some of the discoveries IAVI and partners made in the latter half of 2017 and a look ahead at what’s to come.

What’s missing in HIV vaccine development? If you guessed political will or buy-in from pharmaceutical companies, you’d be wrong. According to Fran Priddy, IAVI’s Chief Medical Officer, it’s actually the virus itself, she explained at AtlanticLIVE’s Vaccines + Immunity event on November 9 in Philadelphia. The event convened top health officials and vaccine experts from…

Two new discoveries by scientists with IAVI's Neutralizing Antibody Center at Scripps could have implications for development of both a vaccine and long-acting HIV prevention.

Natural-infection studies in Africa and India continue to inform HIV vaccine design.

A paper by IAVI's Devin Sok in Nature explores similarities between cow antibodies and HIV antibodies seen in humans.

IAVI scientists demonstrate how to produce a variety of HIV surface protein variants.